Helix BioPharma Corp. Announces Voting Results from its Annual General and Special Meeting

Core Viewpoint - Helix BioPharma Corp. held its Annual General and Special Meeting on March 26, 2025, where shareholders voted overwhelmingly in favor of all proposed resolutions, indicating strong support for the company's strategic direction and governance [1][2]. Voting Results - A total of 40,294,667 common shares were voted, representing 76.00% of the total issued and outstanding shares [1]. - All four director nominees were re-elected with votes in favor ranging from 99.99% to 99.99% [2]. - The appointment of Clearhouse LLP as the auditor was approved with 99.61% of votes in favor [2]. - The asset transactions with Laevoroc Immunology AG and Laevoroc Chemotherapy AG were approved with 99.61% of votes in favor [3]. - The equity draw-down subscription facility providing access to CA$25,000,000 was approved with 99.61% of votes in favor [4]. - The amendment for share consolidation on a ratio of up to five pre-consolidation shares for one post-consolidation share was approved with 99.98% of votes in favor [5]. - The resolution to change the company's name to "Aconara Pharma Corp." was approved with 99.60% of votes in favor [6]. - The approval of unallocated options and the Equity Compensation Plan for a further three years was approved with 99.60% of votes in favor [7]. Company Overview - Helix BioPharma is focused on developing novel therapies for hard-to-treat cancers, with a pipeline that includes the lead candidate Tumour Defence Breaker™ L-DOS47, which targets CEACAM6-expressing solid tumors [10].